A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Tanaka, Kazunori ^a   Kanno, Takuya ^a   Yanagisawa, Yoshiko ^a   Yasutake, Kaori ^a   Inoue, Satoshi ^b   Hirayama, Noriaki ^c   Ikeda, Joh E ^a,c,d  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [MESITYL(METHYL)AMINO] N [4 (PYRIDIN 2 YL) 1H IMIDAZOL 2 YL]ACETAMIDE TRIHYDROCHLORIDE; GLUTATHIONE; IMIDAZOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NEURONAL APOPTOSIS INHIBITORY PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WN 1316;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; GENE EXPRESSION; GLIOSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUMBAR SPINAL CORD; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUSE; MUSCLE NECROSIS; MYOFIBROSIS; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; QUADRICEPS FEMORIS MUSCLE; SPINAL CORD VENTRAL HORN; SURVIVAL RATE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; IMIDAZOLES; INFLAMMATION; MICE; MUSCLE, SKELETAL; NERVE TISSUE PROTEINS; SPINAL CORD;

EID: 84900390805     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087728     Document Type: Article

References (44)

1. Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819. (Pubitemid 33674062)
2. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62. (Pubitemid 23087289)
3. Pratt AJ, Getzoff ED, Perry JJ (2012) Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis 2012: 1-14.
4. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585-591. (Pubitemid 24065791)
5. Miller RG, Mitchell JD, Lyon M, Moore DH (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev: CD001447.
6. Barber SC, Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48: 629-641.
7. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, et al. (1996) Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379: 349-353. (Pubitemid 26033078)
8. Xu DG, Crocker SJ, Doucet JP, St-Jean M, Tamai K, et al. (1997) Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med 3: 997-1004. (Pubitemid 27391954)
9. Okada Y, Sakai H, Kohiki E, Suga E, Yanagisawa Y, et al. (2005) A dopamine D4 receptor antagonist attenuates ischemia-induced neuronal cell damage via upregulation of neuronal apoptosis inhibitory protein. J Cereb Blood Flow Metab 25: 794-806. (Pubitemid 40905607)
10. Tanaka K, Kanno T, Yanagisawa Y, Yasutake K, Hadano S, et al. (2011) Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 232: 41-52.
11. Tanaka K, Okada Y, Kanno T, Otomo A, Yanagisawa Y, et al. (2008) A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Exp Neurol 211: 378-386.
12. Esposito EX, Hopfinger AJ, Madura JD (2004) Methods for applying the quantitative structure-activity relationship paradigm. Methods Mol Biol 275: 131-214.
13. Horio K, Muta H, Goto J, Hirayama N (2007) A simple method to improve the odds in finding 'lead-like' compounds from chemical libraries. Chem Pharm Bull (Tokyo) 55: 980-984. (Pubitemid 47026529)
14. Kanno T, Tanaka K, Yanagisawa Y, Yasutake K, Hadano S, et al. (2012) A novel small molecule, N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6- trimethylphenoxy) acetamide, selectively protects against oxidative stress-induced cell death by activating the Nrf2-ARE pathway: Therapeutic implications for ALS. Free Radic Biol Med 53: 2028-2042.
15. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86. (Pubitemid 29045117)
16. Itoh K, Wakabayashi N, Katoh Y, Ishii T, O'Connor T, et al. (2003) Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8: 379-391. (Pubitemid 36504013)
17. Warabi E, Takabe W, Minami T, Inoue K, Itoh K, et al. (2007) Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species. Free Radic Biol Med 42: 260-269. (Pubitemid 44959746)
18. Jyrkkanen HK, Kansanen E, Inkala M, Kivela AM, Hurttila H, et al. (2008) Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res 103: e1-9.
19. Babior BM (2004) NADPH oxidase. Curr Opin Immunol 16: 42-47.
20. Hall ED, Oostveen JA, Gurney ME (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23: 249-256. (Pubitemid 28259722)
21. Kawamata T, Akiyama H, Yamada T, McGeer PL (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140: 691-707.
22. Schiffer D, Cordera S, Cavalla P, Migheli A (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 139 Suppl: 27-33.
23. Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, et al. (1996) Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19: 797-798.
24. Fischer LR, Glass JD (2007) Axonal degeneration in motor neuron disease. Neurodegener Dis 4: 431-442. (Pubitemid 47557285)
25. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, et al. (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147: 61-69.
26. Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295.
27. Rushmore TH, Morton MR, Pickett CB (1991) The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266: 11632-11639. (Pubitemid 21906996)
28. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA (2003) Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278: 12029-12038. (Pubitemid 36800179)
29. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, et al. (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029. (Pubitemid 30366908)
30. Imhoff BR, Hansen JM (2009) Extracellular redox status regulates Nrf2 activation through mitochondrial reactive oxygen species. Biochem J 424: 491-500.
31. Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT (2010) Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. Chem Biol 17: 75-85.
32. Kim KH, Jeong JY, Surh YJ, Kim KW (2010) Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes. Nucleic Acids Res 38: 48-59.
33. Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, et al. (2010) Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J 24: 2533-2545.
34. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
35. McGeer PL, McGeer EG (2002) Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowledge Environ 2002: re3.
36. Lewis CA, Manning J, Rossi F, Krieger C (2012) The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells. Neurol Res Int 2012: 803701.
37. Moisse K, Strong MJ (2006) Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1083-1093. (Pubitemid 44750573)
38. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, et al. (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29: 824-828.
39. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, et al. (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251-253. (Pubitemid 351311795)
40. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69. (Pubitemid 46011999)
41. Liu Y, Hao W, Dawson A, Liu S, Fassbender K (2009) Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem 284: 3691-3699.
42. Turner BJ, Talbot K (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85: 94-134.
43. Limpert AS, Mattmann ME, Cosford ND (2013) Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). Beilstein journal of organic chemistry 9: 717-732.
44. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11: 38-45.